Biotechnology News NAGLAZYME Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-7 out of 7 found

Current Search: naglazyme: 7

BioMarin and Summit plc Sign Worldwide Licensing Agreement for Duchenne Muscular Dystrophy Program
BioMarin Pharmaceutical Inc.

(Nasdaq and SWX: BMRN) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive worldwide licensing agreement for Summits novel preclinical candidate SMT C1100 and all...

Pharmalive.com: Jul 23 2008 1:10AM
Matching: naglazyme

Find similar documents

BioMarin and Summit plc Sign Worldwide Licensing Agreement for Duchenne Muscular Dystrophy Program
NOVATO, Calif.

and OXFORD, England, July 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.

(Nasdaq and SWX: BMRN - News News) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive...

Yahoo!: Jul 22 2008 1:17PM
Matching: naglazyme

Find similar documents

Surprising Success In Biotech
Article:Firm thrives making drugs for rare conditions:/c/a/2008/07/12/BUN811C1EE.DTL Home of the San Francisco Chronicle Home Delivery| Today's Paper | Ads SFGate Web Search by YAHOO!

| Advanced Search Quick links to the best of SFGate |...

San Francisco Chronicle: Jul 13 2008 4:59PM
Matching: naglazyme

Find similar documents

BioMarin to Present at the Collins Stewart Growth Conference
NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.

(Nasdaq and SWX: BMRN - News News) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Collins...

PR Newswire via Yahoo!: Jul 1 2008 1:45PM
Matching: naglazyme

Find similar documents

S&P: BioMarin Pharmaceutical Inc. B- Corporate Credit Rating Affirmed; Outlook Revised To Positive
'The outlook revision reflects BioMarin's improving financial performance, based on strong sales growth of its three key products,' said Standard & Poor's credit analyst Arthur Wong.

Our speculative-grade rating on BioMarin...

Pharma Live: Jun 25 2008 6:03PM
Matching: naglazyme

Find similar documents

Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f
4:10 PM ET DUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to...

Business Week: Jun 18 2008 11:43AM
Matching: naglazyme

Find similar documents

Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to success in the...

Business Wire via Yahoo!: Jun 18 2008 10:42AM
Matching: naglazyme

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.